Hormonal
Type 2 diabetes mellitus is associated with a significantly higher prevalence of sarcopenia (defined by low lean mass and muscle weakness) compared to healthy controls, independent of diabetes duration or glycemic control.
If you have Type 2 Diabetes, you are at significantly higher risk for muscle loss than someone without diabetes, even if your blood sugar is well-controlled. This loss is not just 'aging'; it is a specific complication of the disease. You should ask your doctor to check your muscle strength (e.g., handgrip) and lean mass, as early detection allows for rehabilitation to restore physical capacity.
Sarcopenia was diagnosed in 13 (16.2%) patients in the DG and 2 (2.4%) in the CG (p = 0.012)... no association with diabetes duration or control.
Why this rating
Cross-sectional study with matched controls, but observational design limits causal inference.
Source
Sarcopenia: a chronic complication of type 2 diabetes mellitus
Heloísa Trierweiler et al. · Diabetology & Metabolic Syndrome · 2018
DOI 10.1186/s13098-018-0326-5
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →